Basics

How Do GLP-1 Medications Work? The Science Explained Simply

GLP-1 Companion · 7 min read

GLP-1 medications have become some of the most talked-about drugs in modern medicine. But beyond the headlines, how do they actually work inside your body? This article explains the science in straightforward terms so you can make informed decisions about your treatment.

The Incretin System: Your Body's Built-In Appetite Controller

To understand GLP-1 medications, you first need to understand the incretin system. Incretins are hormones released by your gut after you eat. Their primary job is to tell your pancreas to produce insulin and to help your body manage the influx of nutrients from a meal.

The two main incretin hormones are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, they account for up to 70 percent of the insulin your body produces after a meal, a phenomenon scientists call the "incretin effect." In people with type 2 diabetes or obesity, this incretin effect is often blunted, meaning the body does not respond to food intake as efficiently.

GLP-1 and GIP: Two Hormones, One Goal

GLP-1 is produced by L-cells in the lower small intestine and colon. It enhances insulin secretion, suppresses glucagon, slows stomach emptying, and signals the brain to reduce hunger. GIP is produced by K-cells in the upper small intestine and also boosts insulin release, though its effects on appetite are less well understood.

Newer medications like tirzepatide (Mounjaro, Zepbound) are dual agonists, meaning they activate both GLP-1 and GIP receptors simultaneously. This dual action appears to produce even greater metabolic benefits and weight loss than targeting GLP-1 alone.

How GLP-1 Medications Signal the Brain

One of the most powerful effects of GLP-1 medications is their action in the brain. GLP-1 receptors are present throughout the central nervous system, particularly in areas that regulate appetite and reward.

The Hypothalamus: Your Hunger Thermostat

The hypothalamus acts as the brain's control center for energy balance. It integrates signals from hormones like leptin, ghrelin, and GLP-1 to decide whether you feel hungry or full. GLP-1 medications activate receptors in the hypothalamus that promote satiety, effectively turning down the "hunger dial." Patients frequently describe feeling satisfied with much smaller portions than they previously ate.

The Brainstem: Controlling Nausea and Fullness

The nucleus tractus solitarius (NTS) in the brainstem is another key target. This region receives signals from the gut via the vagus nerve and from GLP-1 in the bloodstream. Activation of GLP-1 receptors in the NTS reinforces feelings of fullness and can also trigger nausea, which is why gastrointestinal side effects are common, especially during dose escalation.

The Reward System: Changing Your Relationship with Food

Emerging research suggests that GLP-1 medications also affect the mesolimbic reward pathway, the same brain circuit involved in pleasure and addiction. This may explain why many patients report reduced cravings for highly palatable, calorie-dense foods like sweets, fried foods, and alcohol. Some researchers are even exploring GLP-1 medications as potential treatments for alcohol and substance use disorders.

Insulin and Glucagon Regulation

At the level of the pancreas, GLP-1 medications enhance insulin secretion from beta cells in a glucose-dependent manner. This means insulin is released only when blood sugar is elevated, which significantly reduces the risk of hypoglycemia compared to older diabetes drugs like sulfonylureas.

Simultaneously, these medications suppress the release of glucagon from alpha cells. Glucagon normally tells the liver to release stored glucose, so suppressing it helps prevent blood sugar spikes after meals. The combined effect of more insulin and less glucagon creates a powerful glucose-lowering response.

What the Clinical Trials Show

The effectiveness of GLP-1 medications has been validated through large, rigorous clinical trials. Here are some of the landmark results:

• STEP 1 (Wegovy): Participants lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% with placebo.
• STEP 2 (Wegovy in type 2 diabetes): Average weight loss of 9.6% in patients with both obesity and diabetes.
• SURMOUNT-1 (Zepbound): Participants on the highest dose lost an average of 22.5% of body weight over 72 weeks.
• SUSTAIN 6 (Ozempic): Demonstrated a 26% reduction in major adverse cardiovascular events in patients with type 2 diabetes.
• SELECT (Wegovy): Showed a 20% reduction in major cardiovascular events in people with obesity but without diabetes.

The SELECT trial was a landmark moment because it proved that semaglutide reduces heart attacks and strokes in people with obesity, independent of its effects on blood sugar. This expanded the rationale for treating obesity as a serious medical condition.

Why the Slow Dose Escalation?

If you have started or are about to start a GLP-1 medication, you will notice that the dosing increases gradually over several weeks or months. This is not arbitrary. Slow dose escalation allows your gastrointestinal system to adjust to the medication, reducing the severity of nausea, vomiting, and other side effects. It also allows your healthcare provider to find the lowest effective dose for your specific needs.

1. Start at the lowest available dose for the first four weeks.
2. Increase to the next dose level if the current dose is tolerated well.
3. Continue escalating at four-week intervals until the maintenance dose is reached.
4. If side effects are severe, remain at the current dose for an additional four weeks before escalating.

Do the Effects Last After Stopping?

One important consideration is that the benefits of GLP-1 medications are generally maintained only while taking the drug. Studies have shown that patients who discontinue semaglutide regain approximately two-thirds of the weight they lost within one year of stopping. This is because the medication addresses the biological drivers of obesity but does not permanently change them. For this reason, many experts view GLP-1 therapy as a long-term or even lifelong treatment for appropriate candidates.

Key Takeaways

• GLP-1 medications mimic natural incretin hormones to regulate appetite, insulin, and digestion.
• They work in the brain to reduce hunger, curb cravings, and promote feelings of fullness.
• Clinical trials show average weight loss of 15 to 22 percent of body weight depending on the medication.
• These drugs also provide cardiovascular protection, even in patients without diabetes.
• The effects depend on continued use; weight regain is common after discontinuation.

Sources

• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.
• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.